AMD

Notal Vision’s device was given to 15 patients to track changes in their neovascular age-related macular degeneration for the study.

Apellis will seek re-examination from the CHMP following the opinion, according to a news release.

The company expects enrollment of the GAZE phase 1, open-label clinical trial, to begin in the second half of 2024.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, 121,523 of which had no history of AMD.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

The study evaluated the effects of long-term, low-dose aspirin administration in over 3000 older adults.

Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.

The SCANLY Home OCT device allows physicians to monitor patients’ wet age-related macular degeneration in between visits through a health cloud portal.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The South Korean study found that those with age-related macular degeneration may be more at risk of developing some cancers, like renal and thyroid.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

The clinical-stage biopharmaceutical company is running 2 Phase 3 clinical trials, COAST and ShORe, to assess the efficacy and safety of using combinations of certain drugs to treat wet age-related macular degeneration.

AREDS2 supplementation and close monitoring of gut microbiota may help patients at risk for vision loss.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

When a patient has low contrast sensitivity, it means they have difficulty perceiving and distinguishing objects or patterns with subtle differences in contrast. This can have several implications for their vision and daily life, since our world is not merely black and white.

The agreement redefines participant requirements and a slightly increased daily release of the drug, which is currently in a Phase 3 clinical trial.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

A rapid-fire, top-level review of what happened in optometry in 2023.